Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of MK-8527 in Healthy Lactating Females
NCT06580587Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mk-8527 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to 120 hours in Breast Milk, Maximum Breast Milk Concentration up to 21 days and 1 more. Started Apr 2025; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06580587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580587.